In Brief: laxatives warning, FTC settlement, ChromaDex inks 5LINX deal
This article was originally published in The Tan Sheet
Executive Summary
Sodium phosphate laxatives linked to SAERs; FTC scrutinizes personalized supplement claims; NAD refers Xlear LLC to FTC; ChromaDex inks marketing deal with 5LINX; CVS launches vitamin sales, info hub on its website; Star Scientific shareholder suit proceeds.
You may also be interested in...
Pediatric OTC Cough/Cold Rulemaking Absent From FDA Regulatory Agenda
The Spring 2015 unified agenda lists June for a final rule on deeming electronic cigarettes and other alternatives to traditional cigarettes and smokeless tobacco products subject to FDA regulation. FDA adds an item to create a single set of regulations on fixed-combination Rx and OTC drugs.
Pediatric OTC Cough/Cold Rulemaking Absent From FDA Regulatory Agenda
The Spring 2015 unified agenda lists June for a final rule on deeming electronic cigarettes and other alternatives to traditional cigarettes and smokeless tobacco products subject to FDA regulation. FDA adds an item to create a single set of regulations on fixed-combination Rx and OTC drugs.
Industry News Roundup
Speech supplement firm stifled; Botanical Adulterants Program guidance debuts; Fruitful supplements, app launch; Bulu partners with bug protein firm; Healthy Mama extends line; Unilever acquires P&G’s Camay; demand soars for prebiotic infant food supplement; Axiom adds facility, appoints medical board chief; Kefir national ads debut during Golden Globes; and direct selling veteran heads foru.